Marengo Therapeutics, Inc.

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1/2
TCR Vβ6/Vβ10 and IL-2 receptor (IL2R)Multispecific antibody
Non-Small Cell Lung CancerBreast Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
January 2027 (1)
Invikafusp alfaPhase 1/2Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Est. primary completion 2027-01 · NCT06827613 · CT.gov ↗
What to watch
September 2027 (1)
Invikafusp alfaPhase 1/2Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection …
Est. primary completion 2027-09 · NCT05592626 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.